Project description:We performed genome-wide gene expression data of high-grade osteosarcoma cell lines, as well as on mesenchymal stem cells, and osteoblasts, and performed global test analysis in order to determine the most significantly affected KEGG pathways. Genome-wide gene expression analysis was performed on 19 high-grade osteosarcoma cell lines. Significantly differentially expressed genes were determined between osteosarcoma cells and two different sets of control samples - osteoblasts [n=3, GEO accession number GSE33382] and mesenchymal stem cells [n=12, GEO accession number GSE28974]. Global test was applied to the different analyses, in order to determine the most affected signaling pathways in osteosarcoma cells.
Project description:Genome-wide mRNA analysis substantiates high-grade central osteosarcoma cell lines and xenografts as representative for their originating primary tumor type
Project description:We performed genome-wide gene expression data of high-grade osteosarcoma cell lines, as well as on mesenchymal stem cells, and osteoblasts, and performed global test analysis in order to determine the most significantly affected KEGG pathways.
Project description:Gene expression profiling of immortalized human mesenchymal stem cells with hTERT/E6/E7 transfected MSCs. hTERT may change gene expression in MSCs. Goal was to determine the gene expressions of immortalized MSCs.
Project description:Transcriptional profiling of human mesenchymal stem cells comparing normoxic MSCs cells with hypoxic MSCs cells. Hypoxia may inhibit senescence of MSCs during expansion. Goal was to determine the effects of hypoxia on global MSCs gene expression.
Project description:High-grade osteosarcoma is a malignant primary bone tumor with a peak incidence in puberty. Overall survival of patients with metastatic disease is approximately twenty percent. Mechanisms behind the development of metastases in osteosarcoma are unknown. To identify gene signatures that play a role in metastasis, we performed genome-wide gene expression profiling on pre-chemotherapy biopsies of osteosarcoma patients who developed metastases within 5yrs and patients who did not develop metastases within 5yrs.
